antrafenine   Click here for help

GtoPdb Ligand ID: 14685

Synonyms: Compound 45 [PMID: 458805] | SL 73-033 | SL73-033 | Stakane®
Approved drug
antrafenine is an approved drug
Compound class: Synthetic organic
Comment: Antrafenine is an old drug that has analgesic and anti-inflammatory properties [3]. More recently (2025) antrafenine was reported to reduce KNa1.1 (KCNT1) channel activity in vitro, and to reduce seizure activity in a Drosophila model of KCNT1-related epilepsy (caused by gain‐of‐function KCNT1 mutations), leading to the hypothesis that suppressing the overactive channels offers a novel therapeutic intervention for this form of genetic epilepsy [4].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 10
Topological polar surface area 57.17
Molecular weight 588.54
XLogP 4.07
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1=CC(=C(C=C1)NC2=CC=NC3=CC(=CC=C23)C(F)(F)F)C(=O)OCCN4CCN(CC4)C5=CC(=CC=C5)C(F)(F)F
Isomeric SMILES C1CN(CCN1CCOC(=O)C2=CC=CC=C2NC3=C4C=CC(=CC4=NC=C3)C(F)(F)F)C5=CC=CC(=C5)C(F)(F)F
InChI InChI=1S/C30H26F6N4O2/c31-29(32,33)20-4-3-5-22(18-20)40-14-12-39(13-15-40)16-17-42-28(41)24-6-1-2-7-25(24)38-26-10-11-37-27-19-21(30(34,35)36)8-9-23(26)27/h1-11,18-19H,12-17H2,(H,37,38)
InChI Key NWGGKKGAFZIVBJ-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
The use of antrafenine as an analgesic and anti-inflammatory drug [2] has largely been replaced by newer drugs. It was never approved by the US FDA, EU EMA or Japan's PMDA. It was used in France but was withdrawn due to significant adverse effects such as renal toxicity.
The FDA granted orphan designation for antrafenine to be used to treat KCNT1-related epilepsy in October 2024 [1].